Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.51 |
| ▸ | TACR2 | P21452 | 14/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139915 | 0.89 | TACR3 (0.48) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL6999594 | 0.89 | TACR3 (0.43) | TACR3TACR2OPRM1KCNH2 | |
| SCHEMBL28773315 | 0.87 | TACR3 (0.55) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL7003931 | 0.84 | TACR3 (0.53) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL27724853 | 0.84 | TACR3 (0.64) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL6966538 | 0.83 | TACR2 (0.55) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL6969817 | 0.83 | TACR3 (0.49) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL5908979 | 0.83 | TACR2 (0.56) | TACR3TACR2OPRM1KCNH2 | |
| SCHEMBL6627617 | 0.83 | TACR3 (0.46) | TACR3TACR2OPRM1KCNH2TRPV4 | |
| SCHEMBL6963292 | 0.82 | TACR3 (0.53) | TACR3TACR2OPRM1KCNH2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385839-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2004-02-04 | — | — | EP | disclosed |
| EP-1334089-A1 | QUINOLINE DERIVATIVES AS NK-3 AND NK-2 ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002083664-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002038547-A1 | QUINOLINE DERIVATIVES AS NK-3 AND NK-2 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-05-16 | — | — | WO | disclosed |